Prevalence, risk factors and clinical characteristics in patients with genotype 6 chronic hepatitis C: a single institute experience
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, S.K. | - |
dc.contributor.author | Park, S.Y. | - |
dc.contributor.author | Jung, Y.K. | - |
dc.contributor.author | Kim, E.J. | - |
dc.contributor.author | Lee, H.N. | - |
dc.contributor.author | Lee, J.J. | - |
dc.contributor.author | Kwon, O.S. | - |
dc.contributor.author | Choi, D.J. | - |
dc.contributor.author | Kim, Y.S. | - |
dc.contributor.author | Kim, J.H. | - |
dc.date.accessioned | 2021-09-05T00:01:37Z | - |
dc.date.available | 2021-09-05T00:01:37Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/95958 | - |
dc.description.abstract | BACKGROUND/AIMS: Hepatitis C genotypes 1 and 2 are widely distributed globally. In contrast, genotype 6 is found mainly in Southeast Asia, while genotype 6 is rare in Korea. This study aims to investigate the prevalence, risk factors and clinical characteristics of patients with genotype 6 chronic hepatitis C.METHODS: We retrospectively identified 133 HCV-infected patients who underwent HCV genotype analysis between January 2012 and December 2012, and analyzed the prevalence, risk factors and clinical characteristics of patients diagnosed with genotype 6 chronic hepatitis C.RESULTS: Among 133 patients, 53 patients (39.8%) were infected with genotype 1, 62 patients (46.6%) with genotype 2, 2 patients (1.5%) with genotype 3, 14 patients (10.5%) with genotype 6, and 2 patients (1.5%) with mixed genotypes (genotype 1 and 6). The risk factors associated with genotype 6 were acupuncture (n=4, 28.6%), intravenous drug use (n=3, 21.4%), tattoo (n=2, 14.3%), and transfusion (n=2, 14.3%). Of the 14 patients with genotype 6, 6 patients were treated with pegylated interferon and ribavirin. Five patients had reached the end of treatment. All patients reaching end of treatment for genotype 6 showed early virological response and sustained virological response.CONCLUSIONS: The prevalence of genotype 6 is 10.5% and mixed infections of genotype 1 and 6 are 1.5% in patients with chronic hepatitis C. A major potential risk factor is intravenous drug use and the treatment response rate to pegylated interferon plus ribavirin is high in patients with genotype 6 chronic hepatitis C. Large scale multicenter studies are needed. | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.subject | alpha interferon | - |
dc.subject | antivirus agent | - |
dc.subject | macrogol derivative | - |
dc.subject | peginterferon alpha2a | - |
dc.subject | recombinant protein | - |
dc.subject | ribavirin | - |
dc.subject | virus RNA | - |
dc.subject | acupuncture | - |
dc.subject | adult | - |
dc.subject | aged | - |
dc.subject | blood transfusion | - |
dc.subject | combination drug therapy | - |
dc.subject | female | - |
dc.subject | genetics | - |
dc.subject | genotype | - |
dc.subject | Hepacivirus | - |
dc.subject | Hepatitis C, Chronic | - |
dc.subject | human | - |
dc.subject | isolation and purification | - |
dc.subject | male | - |
dc.subject | middle aged | - |
dc.subject | prevalence | - |
dc.subject | retrospective study | - |
dc.subject | risk factor | - |
dc.subject | South Korea | - |
dc.subject | tattooing | - |
dc.subject | Acupuncture Therapy | - |
dc.subject | Adult | - |
dc.subject | Aged | - |
dc.subject | Antiviral Agents | - |
dc.subject | Blood Transfusion | - |
dc.subject | Drug Therapy, Combination | - |
dc.subject | Female | - |
dc.subject | Genotype | - |
dc.subject | Hepacivirus | - |
dc.subject | Hepatitis C, Chronic | - |
dc.subject | Humans | - |
dc.subject | Interferon-alpha | - |
dc.subject | Male | - |
dc.subject | Middle Aged | - |
dc.subject | Polyethylene Glycols | - |
dc.subject | Prevalence | - |
dc.subject | Recombinant Proteins | - |
dc.subject | Republic of Korea | - |
dc.subject | Retrospective Studies | - |
dc.subject | Ribavirin | - |
dc.subject | Risk Factors | - |
dc.subject | RNA, Viral | - |
dc.subject | Tattooing | - |
dc.title | Prevalence, risk factors and clinical characteristics in patients with genotype 6 chronic hepatitis C: a single institute experience | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Y.K. | - |
dc.identifier.doi | 10.4166/kjg.2015.65.2.105 | - |
dc.identifier.scopusid | 2-s2.0-85015354646 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v.65, no.2, pp.105 - 111 | - |
dc.relation.isPartOf | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.title | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.volume | 65 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 105 | - |
dc.citation.endPage | 111 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | alpha interferon | - |
dc.subject.keywordPlus | antivirus agent | - |
dc.subject.keywordPlus | macrogol derivative | - |
dc.subject.keywordPlus | peginterferon alpha2a | - |
dc.subject.keywordPlus | recombinant protein | - |
dc.subject.keywordPlus | ribavirin | - |
dc.subject.keywordPlus | virus RNA | - |
dc.subject.keywordPlus | acupuncture | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | blood transfusion | - |
dc.subject.keywordPlus | combination drug therapy | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | genetics | - |
dc.subject.keywordPlus | genotype | - |
dc.subject.keywordPlus | Hepacivirus | - |
dc.subject.keywordPlus | Hepatitis C, Chronic | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | isolation and purification | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | prevalence | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | risk factor | - |
dc.subject.keywordPlus | South Korea | - |
dc.subject.keywordPlus | tattooing | - |
dc.subject.keywordPlus | Acupuncture Therapy | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Antiviral Agents | - |
dc.subject.keywordPlus | Blood Transfusion | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Genotype | - |
dc.subject.keywordPlus | Hepacivirus | - |
dc.subject.keywordPlus | Hepatitis C, Chronic | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Interferon-alpha | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Polyethylene Glycols | - |
dc.subject.keywordPlus | Prevalence | - |
dc.subject.keywordPlus | Recombinant Proteins | - |
dc.subject.keywordPlus | Republic of Korea | - |
dc.subject.keywordPlus | Retrospective Studies | - |
dc.subject.keywordPlus | Ribavirin | - |
dc.subject.keywordPlus | Risk Factors | - |
dc.subject.keywordPlus | RNA, Viral | - |
dc.subject.keywordPlus | Tattooing | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.